United Kingdom IVF Devices and Consumables Market Size, Share, Growth, and Industry Analysis, By Product Type (IVF Devices Incubators Micromanipulators Cryopreservation Equipment Imaging Systems (e.g., Time-Lapse Imaging) Others (IVF Workstations, Laser Systems) , IVF Consumables Culture Media Petri Dishes and Plates Catheters Syringes and Needles Disposable Gloves Other Consumables (Pipettes, Vials, Straws, etc.) ), By Application (Assisted Reproductive Technology (ART) , Fertility Clinics , Research and Academic Institutes , Hospitals and Surgical Centers ) and Forecast, 2026-2034

United Kingdom IVF Devices and Consumables Market Trends

Automation, Cryopreservation and Data-Led Embryology

IVF laboratories are increasingly shifting toward controlled incubation, time-lapse monitoring, cryopreservation and digitally supported embryo assessment. UK activity provides a substantial installed-use base: approximately 77,500 IVF cycles were conducted in 2023, including 42,310 fresh embryo-transfer cycles and 35,202 frozen embryo-transfer cycles. Frozen transfers increased 24% between 2019 and 2023, compared with 3% for fresh transfers, strengthening utilization of cryogenic storage equipment, media, dishes, pipettes and associated laboratory consumables.

Cryopreservation is becoming particularly important as fertility preservation expands. Egg-freezing cycles rose from 2,567 in 2019 to 6,932 in 2023, an increase of approximately 170%, and represented 7% of treatment and storage activity. Embryo storage reached 8,908 cycles in 2023. At the same time, average pregnancy rates reached 39% per frozen embryo transfer, compared with 31% for fresh embryo transfers, supporting demand for increasingly standardized laboratory workflows and sophisticated embryo-handling technologies.

United Kingdom IVF Devices and Consumables Market Drivers

Rising Treatment Activity and Improving IVF Outcomes Accelerate Laboratory Utilization

Increasing treatment volumes and improving clinical outcomes are strengthening utilization of laboratory equipment and single-use supplies. Approximately 83,000 treatment cycles were undertaken in 2023, including around 77,500 IVF cycles and 5,500 DI cycles, while total treatment and storage activity approached 99,000 cycles involving approximately 63,000 patients. IVF births reached about 20,700 in 2023, compared with 8,700 in 2000, and represented 3.1% of UK births. Fresh-transfer pregnancy rates reached 31% nationally and 41% among patients aged 18–34, supporting sustained investment in controlled laboratory environments.

United Kingdom IVF Devices and Consumables Market Restraints

Funding Constraints and Uneven Access Limit Treatment Expansion

Affordability and geographic variation in public funding remain important restraints. The NHS-funded proportion of UK IVF cycles declined from 35% in 2019 to 27% in 2023. England recorded only 24% NHS-funded cycles, compared with 54% in Scotland, 49% in Northern Ireland and 33% in Wales. Within England, NHS funding ranged from 51% in the North East to 20% in London and 18% in the South East and East Midlands, creating material differences in patient access and increasing dependence on privately funded treatment.

United Kingdom IVF Devices and Consumables Market Opportunities

Fertility Preservation and Frozen-Embryo Workflows Expand Equipment Utilization

Fertility preservation creates opportunities for cryogenic systems, storage consumables, culture media and embryo-management technologies. UK egg-freezing activity expanded by approximately 170% from 2019 to 2023, reaching 6,932 cycles, while frozen embryo-transfer procedures reached 35,202 cycles, up 24% from 2019. Storage activity totaled approximately 15,840 cycles in 2023, including 8,908 embryo-storage cycles. These volumes expand recurring requirements for straws, vials, pipettes, media and cryopreservation infrastructure across licensed centres.

Challenges in United Kingdom IVF Devices and Consumables Market

Quality Assurance Requirements Increase Operational Complexity

IVF laboratories operate under stringent requirements because small process variations can affect embryos, patients and outcomes. The UK fertility sector managed approximately 99,000 treatment and storage cycles involving around 63,000 patients in 2023, increasing the importance of traceability, temperature control, consumable quality and laboratory consistency. Multiple births have declined to 3.4%, while preliminary birth rates reached 25% per fresh transfer and 33% per frozen transfer, placing greater emphasis on maintaining reproducible laboratory performance while incorporating new equipment and automation.

United Kingdom IVF Devices and Consumables Market Segmentation

The market is segmented by product type, application, end use, technology and distribution channel. Based on supplied quantitative data, IVF Devices dominate product revenue with 56.19% in 2026, while ART leads applications with approximately 40.21%.

By Product Type

IVF Devices: IVF Devices are valued at USD 136.86 million in 2026, rising from USD 116.04 million in 2025 and forecast to reach USD 512.34 million by 2034, representing a 17.94% CAGR. The category includes incubators, micromanipulators, cryopreservation equipment, imaging systems, IVF workstations and laser systems.

IVF Devices are also the fastest-growing supplied product category at 17.94% CAGR, compared with 17.45% for consumables. Increased laboratory automation, embryo imaging and cryogenic workflows support equipment replacement and capacity expansion.

IVF Consumables: Consumables account for USD 106.70 million in 2026, compared with USD 90.85 million in 2025, and are forecast at USD 386.37 million by 2034, a 17.45% CAGR. Culture media, dishes, catheters, needles, gloves, pipettes, vials and straws generate recurring purchasing requirements.

Within the supplied product categories, the fastest-growing category remains IVF Devices at 17.94% CAGR. No separate numerical CAGR was supplied for individual consumable subcategories; therefore, values for culture media, dishes, catheters or other individual consumables are not estimated.

By Application

Assisted Reproductive Technology: ART is the largest application, valued at USD 97.91 million in 2026, up from USD 83.19 million in 2025, and is forecast to reach USD 360.35 million by 2034 at 17.69% CAGR. It represents approximately 40.21% of the supplied 2026 application total.

Research and Academic Institutes are the fastest-growing supplied application at 17.85% CAGR, reaching USD 140.14 million in 2034 from USD 37.66 million in 2026. Fertility Clinics grow at 17.68%, while Hospitals and Surgical Centers expand at 17.54%.

By End Use

Fertility Clinics represent the operational centre of IVF procedures and therefore intensive users of incubators, imaging equipment, micromanipulation systems and disposable laboratory products. UK licensed clinics performed more than 77,500 IVF cycles in 2023, within nearly 99,000 treatment and storage cycles.

The segmentation also covers Hospitals, Research Laboratories and Diagnostic Centers. No end-use market-size or CAGR table was supplied; consequently, individual end-use revenue and growth rates are not fabricated.

By Technology

Conventional IVF, ICSI, cryopreservation techniques and time-lapse imaging constitute the principal technology categories. Cryopreservation has a strong operational signal, with frozen embryo-transfer cycles increasing 24% between 2019 and 2023 to 35,202 cycles.

No technology-level revenue or CAGR values were supplied. Accordingly, a largest or fastest-growing technology cannot be quantitatively designated without introducing unsupported estimates.

By Distribution Channel

Direct Sales, Distributors and Dealers, and Online Sales comprise the distribution structure. High-value incubators, micromanipulators, imaging and cryogenic systems typically require technical installation and service, while recurring laboratory supplies create repeat procurement volumes.

No distribution-channel market values, shares or CAGR figures were included in the mandatory dataset. Quantitative dominance and fastest-growing-channel claims are therefore withheld rather than inferred.

United Kingdom IVF Devices and Consumables Market Counties Outlook

England

England represents the largest treatment ecosystem by population and clinic concentration, although a specific equipment-and-consumables revenue share was not supplied. Public-funding penetration was 24% of IVF cycles in 2023. Within England, NHS-funded treatment ranged from 51% in the North East to 20% in London and 18% in both the South East and East Midlands, highlighting significant regional differences in treatment financing.

Scotland

Scotland recorded the highest NHS-funded IVF proportion among UK nations at 54% in 2023. This was more than double England's 24% and above Northern Ireland's 49% and Wales' 33%. The supplied market tables do not allocate the USD 243.56 million 2026 total across individual UK nations, so a Scotland revenue contribution is not estimated.

Wales

Wales recorded an NHS-funded proportion of 33% of IVF cycles in 2023, nine percentage points above England but 21 points below Scotland. Treatment activity contributes to recurring requirements for culture media, cryopreservation products and laboratory disposables; however, no Wales-specific revenue or production figure was supplied.

Northern Ireland

Northern Ireland recorded 49% NHS-funded IVF cycles in 2023, the second-highest national proportion after Scotland's 54%. This compares with 33% in Wales and 24% in England. Separate Northern Ireland market revenue, equipment-production volume and sector share were not supplied and are therefore not estimated.

Top players in United Kingdom IVF Devices and Consumables Market

• CooperSurgical, Inc.
• Vitrolife AB
• Thermo Fisher Scientific Inc.
• Cook Medical
• Hamilton Thorne Ltd.
• Esco Medical
• Kitazato Corporation
• FUJIFILM Irvine Scientific
• Genea Biomedx
• Nikon Corporation
• Olympus Corporation
• Eppendorf SE
• Merck KGaA
• Gynemed GmbH & Co. KG
• Rocket Medical plc

Top Two Companies

• CooperSurgical

CooperSurgical holds a prominent competitive position through IVF laboratory equipment, micromanipulation, embryo-transfer, genetic and fertility-related product capabilities. The company competes across high-frequency consumables and capital equipment used through multiple stages of assisted reproduction. With UK IVF activity exceeding77,500 cycles in 2023and frozen embryo transfers reaching35,202 cycles, suppliers with broad workflow portfolios are positioned to address both installed-equipment and recurring-consumable requirements. A verified UK-specific company revenue share was not supplied or publicly established in the reviewed evidence; therefore, assigning a percentage would be speculative.

• Vitrolife AB

Vitrolife maintains a major European assisted-reproduction position spanning culture media, time-lapse systems, cryopreservation and reproductive genetics. Its strategic emphasis on IVF automation and digitalization aligns with increasingly data-intensive laboratory workflows. UK egg-freezing procedures reached6,932 cycles in 2023, up approximately170% from 2019, while frozen embryo-transfer cycles increased 24% over the same period, supporting demand for cryopreservation and embryo-management solutions. A reliable UK-specific percentage share for Vitrolife was not provided in the mandatory dataset; no unsupported share estimate is assigned.

Recent Developments in United Kingdom IVF Devices and Consumables Market

• 2026:Research into multimodal AI for embryo development advanced with InVitroVision, demonstrating the continuing movement toward automated interpretation of time-lapse embryo imagery and data-supported laboratory decision-making.
• 2025:HFEA's 2024/25 sector reporting showed approximately99,000 treatment and storage cyclesin 2023 involving about 63,000 patients, underscoring the scale of the regulated UK fertility laboratory ecosystem.
• 2025:Updated HFEA treatment statistics reported more than77,500 IVF cyclesand approximately 20,700 IVF births during 2023, with IVF accounting for3.1% of UK births.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 providing historical context. Mandatory market values supplied for this report were treated as the primary quantitative dataset: total product revenue progresses from USD 206.89 million in 2025 to USD 243.56 million in 2026 and USD 898.71 million in 2034, corresponding to a supplied CAGR of 17.69%. Application totals show USD 206.88 million, USD 243.47 million and USD 896.12 million for the respective years; the small difference from product totals is retained exactly as supplied rather than reconciled artificially. Segment percentages were calculated directly from supplied values. Operational indicators were cross-checked against HFEA publications covering IVF cycles, patients, treatment types, outcomes, cryopreservation and NHS funding. No unsupported country, technology, end-use, distribution-channel or company market shares were manufactured where primary numerical data were unavailable.